12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Invida, Roche sales and marketing update

Invida received Korean commercialization rights to Roche's primary care portfolio, which includes obesity drug Xenical orlistat, acne drug...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >